1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Tafamidis Drugs Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Tafamidis Free Acid
  • 1.3.3 Tafamidis Meglumine
• 1.4 Market Analysis by Application
  • 1.4.1 Overview: Global Tafamidis Drugs Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.4.2 ATTR-PN
  • 1.4.3 ATTR-CM
  • 1.4.4 Other
• 1.5 Global Tafamidis Drugs Market Size & Forecast
  • 1.5.1 Global Tafamidis Drugs Consumption Value (2021 & 2025 & 2032)
  • 1.5.2 Global Tafamidis Drugs Sales Quantity (2021-2032)
  • 1.5.3 Global Tafamidis Drugs Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Pfizer
  • 2.1.1 Pfizer Details
  • 2.1.2 Pfizer Major Business
  • 2.1.3 Pfizer Tafamidis Drugs Product and Services
  • 2.1.4 Pfizer Tafamidis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Pfizer Recent Developments/Updates
• 2.2 Qilu pharmaceutical
  • 2.2.1 Qilu pharmaceutical Details
  • 2.2.2 Qilu pharmaceutical Major Business
  • 2.2.3 Qilu pharmaceutical Tafamidis Drugs Product and Services
  • 2.2.4 Qilu pharmaceutical Tafamidis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.2.5 Qilu pharmaceutical Recent Developments/Updates
• 2.3 Chia Tai Tianqing Pharmaceutical
  • 2.3.1 Chia Tai Tianqing Pharmaceutical Details
  • 2.3.2 Chia Tai Tianqing Pharmaceutical Major Business
  • 2.3.3 Chia Tai Tianqing Pharmaceutical Tafamidis Drugs Product and Services
  • 2.3.4 Chia Tai Tianqing Pharmaceutical Tafamidis Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.3.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Tafamidis Drugs by Manufacturer

• 3.1 Global Tafamidis Drugs Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Tafamidis Drugs Revenue by Manufacturer (2021-2026)
• 3.3 Global Tafamidis Drugs Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Tafamidis Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Tafamidis Drugs Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Tafamidis Drugs Manufacturer Market Share in 2025
• 3.5 Tafamidis Drugs Market: Overall Company Footprint Analysis
  • 3.5.1 Tafamidis Drugs Market: Region Footprint
  • 3.5.2 Tafamidis Drugs Market: Company Product Type Footprint
  • 3.5.3 Tafamidis Drugs Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Tafamidis Drugs Market Size by Region
  • 4.1.1 Global Tafamidis Drugs Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Tafamidis Drugs Consumption Value by Region (2021-2032)
  • 4.1.3 Global Tafamidis Drugs Average Price by Region (2021-2032)
• 4.2 North America Tafamidis Drugs Consumption Value (2021-2032)
• 4.3 Europe Tafamidis Drugs Consumption Value (2021-2032)
• 4.4 Asia-Pacific Tafamidis Drugs Consumption Value (2021-2032)
• 4.5 South America Tafamidis Drugs Consumption Value (2021-2032)
• 4.6 Middle East & Africa Tafamidis Drugs Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Tafamidis Drugs Sales Quantity by Type (2021-2032)
• 5.2 Global Tafamidis Drugs Consumption Value by Type (2021-2032)
• 5.3 Global Tafamidis Drugs Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Tafamidis Drugs Sales Quantity by Application (2021-2032)
• 6.2 Global Tafamidis Drugs Consumption Value by Application (2021-2032)
• 6.3 Global Tafamidis Drugs Average Price by Application (2021-2032)

7 North America

• 7.1 North America Tafamidis Drugs Sales Quantity by Type (2021-2032)
• 7.2 North America Tafamidis Drugs Sales Quantity by Application (2021-2032)
• 7.3 North America Tafamidis Drugs Market Size by Country
  • 7.3.1 North America Tafamidis Drugs Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Tafamidis Drugs Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Tafamidis Drugs Sales Quantity by Type (2021-2032)
• 8.2 Europe Tafamidis Drugs Sales Quantity by Application (2021-2032)
• 8.3 Europe Tafamidis Drugs Market Size by Country
  • 8.3.1 Europe Tafamidis Drugs Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Tafamidis Drugs Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Tafamidis Drugs Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Tafamidis Drugs Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Tafamidis Drugs Market Size by Region
  • 9.3.1 Asia-Pacific Tafamidis Drugs Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Tafamidis Drugs Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Tafamidis Drugs Sales Quantity by Type (2021-2032)
• 10.2 South America Tafamidis Drugs Sales Quantity by Application (2021-2032)
• 10.3 South America Tafamidis Drugs Market Size by Country
  • 10.3.1 South America Tafamidis Drugs Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Tafamidis Drugs Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Tafamidis Drugs Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Tafamidis Drugs Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Tafamidis Drugs Market Size by Country
  • 11.3.1 Middle East & Africa Tafamidis Drugs Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Tafamidis Drugs Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Tafamidis Drugs Market Drivers
• 12.2 Tafamidis Drugs Market Restraints
• 12.3 Tafamidis Drugs Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Tafamidis Drugs and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Tafamidis Drugs
• 13.3 Tafamidis Drugs Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Tafamidis Drugs Typical Distributors
• 14.3 Tafamidis Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Tafamidis Drugs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Tafamidis is a pharmaceutical drug prescribed primarily for the treatment of transthyretin amyloidosis(ATTR),a rare and debilitating condition characterized by the abnormal accumulation of transthyretin protein in various tissues.By stabilizing transthyretin tetramers,Tafamidis helps prevent the formation of amyloid fibrils,which are the hallmark of the disease and lead to organ dysfunction,particularly affecting the heart and nerves.
This report is a detailed and comprehensive analysis for global Tafamidis Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Tafamidis Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Tafamidis Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Tafamidis Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Tafamidis Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tafamidis Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tafamidis Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Qilu pharmaceutical, Chia Tai Tianqing Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Tafamidis Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Tafamidis Free Acid
Tafamidis Meglumine
Market segment by Application
ATTR-PN
ATTR-CM
Other
Major players covered
Pfizer
Qilu pharmaceutical
Chia Tai Tianqing Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tafamidis Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tafamidis Drugs, with price, sales quantity, revenue, and global market share of Tafamidis Drugs from 2021 to 2026.
Chapter 3, the Tafamidis Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tafamidis Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Tafamidis Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tafamidis Drugs.
Chapter 14 and 15, to describe Tafamidis Drugs sales channel, distributors, customers, research findings and conclusion.